The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth ...

Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its CFX96 Dx Real-Time PCR System has been listed with ...

Low commission rates start at $0 for U.S. listed stocks & ETFs*. Margin loan rates from 4.14% to 5.14%. Commission-free trading on stocks & ETFs. Earn $+0.06 per options contract and 5.1% APY on cash ...

Bio-Rad’s expansive antibody library platform sets the stage for an innovative and pioneering approach to biotherapeutic antibody discovery ...